THE SCIENCE
Tirzepatide is a dual GIP and GLP-1 receptor agonist that has been studied extensively in relation to glucose regulation, appetite, body weight, and metabolic health. The sections below provide scientific background on its receptor activity, metabolic signaling, and clinical research.
MOLECULAR DESIGN
Tirzepatide is a single peptide designed to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Its dual-receptor activity is a defining feature of its pharmacology.
GIP & GLP-1 RECEPTOR ACTIVITY
Tirzepatide activates both GIP and GLP-1 receptors. Research has examined how combined activation of these pathways may influence glucose regulation, appetite, energy balance, and body weight.
METABOLIC SIGNALING
GIP and GLP-1 receptor signaling influences processes involved in glucose regulation, insulin secretion, appetite, and energy balance. Clinical research on tirzepatide has examined changes in body weight and a range of metabolic measures.
BODY WEIGHT & METABOLIC EFFECTS
- Tirzepatide has been studied extensively for its effects on body weight and metabolic measures. Clinical trials have evaluated changes in body weight, waist circumference, glycemic measures, blood pressure, lipid measures, and other cardiometabolic endpoints.
CLINICAL RESEARCH
The SURMOUNT clinical trial program has evaluated tirzepatide in adults with obesity or overweight, with studies examining changes in body weight and related metabolic outcomes over different treatment periods.
PHASE 3 RESEARCH
In the 72-week SURMOUNT-1 trial, adults with obesity or overweight and a weight-related condition, without diabetes, were randomized to tirzepatide or placebo. Mean treatment-regimen weight change at week 72 was −15.0% with 5 mg, −19.5% with 10 mg, and −20.9% with 15 mg, compared with −3.1% with placebo. The trial also reported improvements in several cardiometabolic measures.